Under the title, What’s Next in Psoriasis? From Maintenance to Disease Modification, the 2022 IPC Think Tank scientific symposium was held on Friday, December 9th, in Miami, Florida. Read the full report or a summary of the five psoriasis focused sessions.
The IPC’s global network of experts generously volunteers their time every year to educate and train other physicians to better care for people with psoriasis. We would like to recognize our top three Councilors that went above and beyond in 2022 to support our work.
The patient perspective has become even more important in the wake of the pandemic. Here’s how Clinica Dermacross is making it a priority.
Dr. Kelly Cordoro’s research on pediatric psoriasis shows it may be time to rethink our expectations about comorbidities and treatment.
In 2022, the IPC advanced in the worldwide psoriasis community, ranging from multiple research efforts, education of dermatologists, and public awareness, reaching the patient communities. In addition to face-to-face events, the IPC has expanded its digital presence. Read some of IPC’s significant achievements from the past year and leave a comment letting us know what topics you want to see on the IPC website in the coming year!
International Psoriasis Councils’ Psoriasis Severity Reclassification Project aims to change the classification of psoriasis severity. IPC’s network of key opinion leaders agreed on a definition for each category of disease severity.
European Commission grants conditional marketing authorization based on the EFFISAYIL® 1 trial, which showed over half of the spesolimab-treated patients were free of pustules, one week after receiving a single dose. This decision builds on existing approvals in the United States and Japan.
Recently, a study was conducted on the effect of apremilast on vascular inflammation and cardiometabolic functions with an impressively comprehensive set of markers for vascular inflammation and cardiometabolic disease. Peter van de Kerkhof, MD, PhD, provides his expert opinion on the overall conclusion and the implications of this study are discussed.
Recurrent flares, painful fiery-red skin, and sterile pustules — are the characteristics of Generalized Pustular Psoriasis (GPP), a rare and potentially life-threatening autoinflammatory disease.